Thomson Medical Group Ltd. (A50) AI Stock Analysis

• Market Cap: S$1.45B
• Dividend Yield: N/A
• Average Volume (3M): 2.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 12.39%
• EPS Growth: -400.00%
• Country: SG
• Employees: 699
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.00
• Shares Outstanding: 26,443,615,000
• 10 Day Avg. Volume: 2,062,170
• 30 Day Avg. Volume: 2,143,033
• PEG Ratio: 0.05
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 2.88
• P/FCF Ratio: 33.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: S$0.06
• Price Target Upside: 0.00%
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: S$0.06 ▼(-8.33% Downside)
• Action: Reiterated Date: 01/08/26
• Date: Action: Reiterated 01/08/26

Overall score is held back primarily by weak financial performance (declining revenue, negative profitability, high leverage, and poor free cash flow trends). Technicals are a bright spot with price trading above major moving averages and positive MACD, but valuation is undermined by losses (negative P/E) and no dividend yield support.

Positive Factors

High gross margin

A 74.83% gross margin indicates a durable service-level pricing advantage and favorable cost structure for hospital services. High gross margins create room to absorb SG&A and operating pressures, supporting margin recovery and resilience as volumes normalize over months.

Specialized market focus

Concentration on obstetrics, gynaecology and paediatrics provides structural demand stability and differentiated clinical expertise. This niche positioning supports steady maternity-driven revenue, higher-margin specialist services and customer loyalty that persist across economic cycles.

Some cash conversion ability

A FCF-to-net-income ratio of 0.56 shows the business can convert a meaningful portion of earnings into cash. While not strong, this structural capability helps fund working capital and patient-service operations, providing partial buffer versus pure accrual losses.

Negative Factors

High leverage

A D/E of 2.38 signals elevated financial risk and limited balance sheet flexibility. High leverage amplifies interest burden and constrains capital allocation, reducing ability to invest in capacity or weather lower patient volumes, especially given weak profitability.

Negative net profitability

A -12.05% net margin reflects persistent profitability challenges that erode equity and limit reinvestment. Continued negative margins undermine long-term sustainability, making it harder to deleverage or fund strategic initiatives without external financing or structural cost improvement.

Weak free cash flow trends

A >600% drop in FCF growth and OC-to-NI of 0.22 indicate poor core cash generation. Structural weakness in cash flow raises refinancing and liquidity risk, constrains capex and working capital funding, and increases dependence on debt or equity to sustain operations.

Thomson Medical Group Ltd. Business Overview & Revenue Model

Company Description

Thomson Medical Group Limited, an investment holding company, provides healthcare services for women and children in Singapore, Malaysia, and Vietnam. The company owns and operates the Thomson Medical Centre, as well as a network of medical clinics and facilities. It also offers urgent care services, such as basic resuscitation, ECG, vaccinations, IM/IV fluid and IV antibiotic administration, surgeries and procedures, wound care and stitching, and X-ray and basic laboratory tests; health screening services; services related to skin and aesthetics, and pain and rehab management; and herbal tea. In addition, the company provides specialized services, such as women's health, children's health, fertility and family planning, eye health, general surgery, urology, preventive health and healthy ageing, diagnostic imaging, breast health, cardiology, respiratory medicine and critical care, endocrinology, dermatology, day surgery, surgical care, counselling and therapy, traditional Chinese medicine (TCM), as well as bone, joint, gynecological oncology, dentistry, and spine health. It offers its products and services under the Thomson Women's Clinic, Thomson Fertility Centre, Thomson Paediatric Clinic, Thomson Specialists, Thomson Chinese Medicine, Thomson Surgical Centre, Thomson Dental Centre, Thomson Hospital Kota Damansara, TMC Fertility, TMC Care Pharmacy, FV Hospital, and FV Saigon Clinic brands. Thomson Medical Group Limited was founded in 1979 and is based in Singapore.

How the Company Makes Money

Thomson Medical Group makes money primarily by charging for healthcare services delivered through its private hospital operations. Key revenue streams typically include (1) inpatient and outpatient clinical fees from consultations, diagnostics, procedures and surgeries provided by specialists and hospital-employed/affiliated clinicians; (2) maternity- and women’s-health related services (e.g., obstetrics and gynaecology care) and paediatric care, where the group earns hospital facility charges and service fees tied to patient admissions, deliveries, and follow-up visits; and (3) ancillary and support services associated with hospital care, such as operating theatre usage, imaging, laboratory tests, pharmacy and other hospital service charges. Additional contributions may come from other healthcare-related businesses or services operated by the group, but specific segment-level breakdowns, pricing structures, and material partnerships are null if not disclosed in publicly available filings or the provided prompt.

Thomson Medical Group Ltd. Financial Statement Overview

Summary

Weak fundamentals: revenue declined (-9.17%), net margin is negative (-12.05%), and leverage is high (debt-to-equity 2.38). Cash flow is also pressured with sharply negative free cash flow growth (-636.22%) and low operating cash flow to net income (0.22), despite a strong gross margin (74.83%).

Income Statement

Thomson Medical Group Ltd. has experienced a decline in revenue growth, with a negative growth rate of -9.17% in the latest year. The gross profit margin remains strong at 74.83%, but the net profit margin has turned negative at -12.05%, indicating profitability challenges. The EBIT and EBITDA margins have also decreased significantly, reflecting operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio has increased to 2.38, indicating high leverage and potential financial risk. Return on equity is negative at -10.10%, highlighting challenges in generating returns for shareholders. The equity ratio stands at 26.38%, suggesting a moderate level of equity financing.

Cash Flow

Free cash flow growth has significantly declined by -636.22%, and the operating cash flow to net income ratio is low at 0.22, indicating cash flow challenges. The free cash flow to net income ratio is 0.56, showing some ability to convert net income into cash flow, but overall cash flow performance is weak.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2021
Income Statement
Total Revenue	394.66M	351.15M	355.77M	333.71M	240.40M
Gross Profit	295.33M	275.39M	296.39M	278.38M	116.02M
EBITDA	57.72M	109.08M	106.78M	110.72M	59.54M
Net Income	-47.58M	14.16M	36.55M	53.76M	14.24M
Balance Sheet
Total Assets	1.78B	1.81B	1.45B	1.36B	1.29B
Cash, Cash Equivalents and Short-Term Investments	124.21M	167.28M	286.59M	161.59M	114.51M
Total Debt	1.12B	1.12B	762.79M	642.86M	631.08M
Total Liabilities	1.24B	1.23B	872.34M	756.60M	719.74M
Stockholders Equity	470.89M	499.72M	499.44M	531.68M	489.84M
Cash Flow
Free Cash Flow	33.79M	52.99M	75.81M	64.68M	23.96M
Operating Cash Flow	60.45M	83.35M	88.59M	92.80M	61.25M
Investing Cash Flow	-27.16M	-489.99M	-13.39M	-29.44M	-37.57M
Financing Cash Flow	-71.19M	281.32M	54.22M	-23.48M	-58.82M

Thomson Medical Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:A50, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.60 is Neutral, neither overbought nor oversold. The STOCH value of 68.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SG:A50.

Thomson Medical Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
A50	46 Neutral	S$1.45B	-23.90	-9.69%	―	12.39%	-400.00%

Thomson Medical Group Ltd. Corporate Events

TMC Life Sciences Issues Unaudited Interim Results for December 2025 Quarter

TMC Life Sciences Berhad has released its unaudited interim financial report for the financial quarter ended 31 December 2025, providing stakeholders with an early view of its financial performance. The disclosure signals the company’s ongoing reporting discipline and offers investors, regulators, and market watchers updated information that may shape expectations ahead of the full-year audited results.

The most recent analyst rating on (SG:A50) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Thomson Medical Group Ltd. stock, see the SG:A50 Stock Forecast page.

Thomson Medical Group Names Tong Kooi Ong as Chairman to Steer Next Growth Phase

Thomson Medical Group has appointed entrepreneur and veteran corporate leader Tong Kooi Ong as Chairman of the Board with effect from 1 February 2026, replacing Ng Ser Miang, who steps down after nearly a decade in the role. The board transition comes as the group moves into its next phase of growth, with management highlighting Tong’s track record in large-scale, capital-intensive developments and his extensive regional business networks as critical assets for advancing Thomson Medical’s leadership in the healthcare sector, including the ambitious Johor Bay project in the Johor–Singapore Special Economic Zone.

The most recent analyst rating on (SG:A50) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Thomson Medical Group Ltd. stock, see the SG:A50 Stock Forecast page.

Thomson Medical Reshapes Board Leadership and Committees

Thomson Medical Group Limited has announced changes to its board leadership, appointing Mr Tong Kooi Ong as Chairman and Independent Non-Executive Director with effect from 1 February 2026, succeeding Mr Ng Ser Miang, who will resign on 31 January 2026. The company is also reconstituting its board committees from 1 February 2026, with updated memberships for the Audit and Risk Committee and the Nominating and Remuneration Committee, signalling a refreshed governance structure that may influence strategic oversight and risk management for shareholders and other stakeholders.

The most recent analyst rating on (SG:A50) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Thomson Medical Group Ltd. stock, see the SG:A50 Stock Forecast page.